{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:04:38Z","timestamp":1790042678359,"version":"4.0.1"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","id":[{"id":"https:\/\/ror.org\/05gqaka33","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Agonists at glucagon-like-peptide-1 receptors (GLP-1R) are becoming approved drugs to treat not only type 2 diabetes and obesity but also cardiac diseases such as coronary heart disease, myocardial infarction and heart failure. Agonism at the GLP-1R can be combined with agonism at additional receptors (co-agonists) to obtain drugs which are more potent to induce weight loss. Therefore, new co-agonists were developed that not solely stimulate GLP-1R. We discuss here the known (for tirzepatide and retatrutide) or predicted contractile effects of such co-agonists on isolated cardiac preparations of experimental animals, mainly in mice and compare these results with data in isolated human cardiac preparations. We point out where preclinical studies in mice may be misleading in order to study cardiac effects of the drugs of interest in the human heart and as potential drugs for heart diseases. We address in some detail which additional receptors are or might be involved, the receptor expression of such additional receptors in the heart of various experimental animals. We will discuss not only receptor agonists but also a receptor antagonist (AMG133). We identify research needs and controversies in the literature. We make suggestions for further preclinical research and what improvements in drug design for treatment may lie ahead.<\/jats:p>","DOI":"10.1007\/s00210-026-05908-3","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:39:32Z","timestamp":1790041172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Future GLP-1 receptor co-agonists and their cardiac effects"],"prefix":"10.1007","author":[{"given":"Joachim","family":"Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Kirchefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Gergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"5908_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2023.107176","volume":"130","author":"MF Abdelmalek","year":"2023","unstructured":"Abdelmalek MF, Suzuki A, Sanchez W, Lawitz E, Filozof C, Cho H, Baek E, Choi J, Baek S (2023b) A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis-study design and rationale of HM-TRIA-201 study. Contemp Clin Trials 130:107176. https:\/\/doi.org\/10.1016\/j.cct.2023.107176","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"5908_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12432","volume":"11","author":"M Alba","year":"2021","unstructured":"Alba M, Yee J, Frustaci ME, Samtani MN, Fleck P (2021) Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study. Clin Obes. 11(2):e12432. https:\/\/doi.org\/10.1111\/cob.12432","journal-title":"Clin Obes."},{"issue":"26","key":"5908_CR3","doi-asserted-by":"publisher","first-page":"18365","DOI":"10.1074\/jbc.M710466200","volume":"283","author":"MC Althage","year":"2008","unstructured":"Althage MC, Ford EL, Wang S, Tso P, Polonsky KS, Wice BM (2008) Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J Biol Chem 283(26):18365\u201376. https:\/\/doi.org\/10.1074\/jbc.M710466200","journal-title":"J Biol Chem"},{"issue":"11","key":"5908_CR4","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.molmet.2017.08.010","volume":"6","author":"LL Baggio","year":"2017","unstructured":"Baggio LL, Ussher JR, McLean BA, Cao X, Kabir MG, Mulvihill EE, Mighiu AS, Zhang H, Ludwig A, Seeley RJ, Heximer SP, Drucker DJ (2017) The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. Mol Metab 6(11):1339\u201349. https:\/\/doi.org\/10.1016\/j.molmet.2017.08.010","journal-title":"Mol Metab"},{"key":"5908_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2025.171380","volume":"187","author":"CJ Bailey","year":"2025","unstructured":"Bailey CJ, Flatt PR, Conlon JM (2025) Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides 187:171380. https:\/\/doi.org\/10.1016\/j.peptides.2025.171380","journal-title":"Peptides"},{"issue":"18","key":"5908_CR6","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","volume":"117","author":"K Ban","year":"2008","unstructured":"Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117(18):2340\u201350. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.739938","journal-title":"Circulation"},{"issue":"4","key":"5908_CR7","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1210\/en.2009-1197","volume":"151","author":"K Ban","year":"2010","unstructured":"Ban K, Kim KH, Cho CK, Sauv\u00e9 M, Diamandis EP, Backx PH, Drucker DJ, Husain M (2010) Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 151(4):1520\u201331. https:\/\/doi.org\/10.1210\/en.2009-1197","journal-title":"Endocrinology"},{"issue":"4","key":"5908_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10557-023-07432-5","volume":"38","author":"M Banerjee","year":"2024","unstructured":"Banerjee M, Maisnam I, Mukhopadhyay S (2024) Impact of heart failure history at baseline on cardiovascular effects of GLP-1 receptor agonists in type 2 diabetes: a meta-analysis. Cardiovasc Drugs Ther 38(4):739\u2013746. https:\/\/doi.org\/10.1007\/s10557-023-07432-5","journal-title":"Cardiovasc Drugs Ther"},{"key":"5908_CR9","first-page":"E459","volume":"266","author":"JM Barragan","year":"1994","unstructured":"Barragan JM, Rodriguez R, Bl\u00e1zquez E (1994) Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-l- (7\u201336) amide in rats. Am J Physiol 266:E459\u2013E466","journal-title":"Am J Physiol"},{"issue":"6898","key":"5908_CR10","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nature00887","volume":"418","author":"RL Batterham","year":"2002","unstructured":"Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418(6898):650\u20134. https:\/\/doi.org\/10.1038\/nature00887","journal-title":"Nature"},{"issue":"3","key":"5908_CR11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/oby.70106","volume":"34","author":"HE Bays","year":"2026","unstructured":"Bays HE, Toth P, Alkhouri N, Pullman J, Freilich B, Neutel J, Ji S, Stubbe S, Hedges P, Lian B (2026) Weekly subcutaneous VK2735, a GIP\/GLP-1 receptor dual agonist, for weight management: phase 2, randomized, 13-week VENTURE study. Obesity (Silver Spring) 34(3):537\u2013549. https:\/\/doi.org\/10.1002\/oby.70106","journal-title":"Obesity (Silver Spring)"},{"issue":"10","key":"5908_CR12","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.hrthm.2021.06.1189","volume":"18","author":"A Bhaskaran","year":"2021","unstructured":"Bhaskaran A, Niri A, Azam MA, Nayyar S, Porta-S\u00e1nchez A, Mass\u00e9 S, Liang T, Veluppillai A, Du B, Lai PFH, Ha A, Nanthakumar K (2021) Safety, efficacy, and monitoring of bipolar radiofrequency ablation in beating myopathic human and healthy swine hearts. Heart Rhythm 18(10):1772\u20131779. https:\/\/doi.org\/10.1016\/j.hrthm.2021.06.1189","journal-title":"Heart Rhythm"},{"key":"5908_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.peptides.2017.12.021","volume":"100","author":"SJ Brandt","year":"2018","unstructured":"Brandt SJ, G\u00f6tz A, Tsch\u00f6p MH, M\u00fcller TD (201) Gut hormone polyagonists for the treatment of type 2 diabetes. Peptides 100:190\u2013201. https:\/\/doi.org\/10.1016\/j.peptides.2017.12.021","journal-title":"Peptides"},{"issue":"11","key":"5908_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101483","volume":"7","author":"SK Browne","year":"2025","unstructured":"Browne SK, Suschak JJ, Tomah S, Gutierrez JA, Yang J, Georges B, Roberts MS, Harris MS (2025) Safety and effi cacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP Rep 7(11):101483. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101483","journal-title":"JHEP Rep"},{"key":"5908_CR15","doi-asserted-by":"publisher","unstructured":"Chakravarthy M, Arg\u00fcelles-Tello FA, Sun ALA, Elliott M, Acosta L, Rankin JE, Hansen SK (2023) 75-LB: CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, is safe, well-tolerated, and produces more than 8% weight loss in four weeks in overweight and obese adults. Diabetes 72(Supplement_1). https:\/\/doi.org\/10.2337\/db23-75-LB","DOI":"10.2337\/db23-75-LB"},{"key":"5908_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102291","volume":"103","author":"MV Chakravarthy","year":"2026","unstructured":"Chakravarthy MV, Rodriguez R, Hergarden A, Elliott MA, Frias JP, Arg\u00fcelles-Tello FA, Tenorio E, Rankin JE, Wu J, Krishnan S, Erlanson DA, Fucini RV, Bone D, Iwig JS, Acosta L, Untereiner A, Pant A, Patton A, Sanchez-Sanchez LL, Luo J, Steinberg A, Bialonczyk D, Hansen SK (2026a) Effects of CT-388, a once-weekly signaling-biased dual GLP-1\/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity. Mol Metab 103:102291. https:\/\/doi.org\/10.1016\/j.molmet.2025.102291","journal-title":"Mol Metab"},{"issue":"3","key":"5908_CR17","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/dom.70006","volume":"28","author":"MV Chakravarthy","year":"2026","unstructured":"Chakravarthy MV, Elliott MA, Acosta L, Sonnenberg GE, Bialonczyk D, Wu J, Arg\u00fcelles-Tello FA, Garcia-Reza R, Gonz\u00e1lez-Gonz\u00e1lez JG, Hansen SK, Frias JP (2026b) Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1\/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial. Diabetes Obes Metab 28(3):1673\u20131682. https:\/\/doi.org\/10.1111\/dom.70006","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"5908_CR18","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/j.1460-9568.2006.05016.x","volume":"24","author":"H Chen","year":"2006","unstructured":"Chen H, Kent S, Morris MJ (2006) Is the CCK2 receptor essential for normal regulation of body weight and adiposity? Eur J Neurosci 24(5):1427\u201333. https:\/\/doi.org\/10.1111\/j.1460-9568.2006.05016.x","journal-title":"Eur J Neurosci"},{"issue":"21","key":"5908_CR19","doi-asserted-by":"publisher","first-page":"12595","DOI":"10.1021\/acs.jmedchem.0c00736","volume":"63","author":"X Chen","year":"2020","unstructured":"Chen X, Fu J, Zhou F, Yang Q, Wang J, Feng H, Jiang W, Jin L, Tang X, Jiang N, Yin J, Han J (2020) Stapled and Xenopus glucagon-like peptide 1 (GLP-1)-based dual GLP-1\/gastrin receptor agonists with improved metabolic benefits in rodent models of obesity and diabetes. J Med Chem 63(21):12595\u201312613. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00736","journal-title":"J Med Chem"},{"issue":"10499","key":"5908_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","volume":"406","author":"K Dahl","year":"2025","unstructured":"Dahl K, Toubro S, Dey S, Duque do Vale R, Flint A, Gasiorek A, Heydorn A, Jastreboff AM, Key C, Petersen SB, Vegge A, Adelborg K (2025) Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study. Lancet 406(10499):149\u2013162. https:\/\/doi.org\/10.1016\/S0140-6736(25)01185-7","journal-title":"Lancet"},{"issue":"19","key":"5908_CR21","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/0024-3205(87)90045-2","volume":"40","author":"JM Danger","year":"1987","unstructured":"Danger JM, Tonon MC, Lamacz M, Martel JC, Saint-Pierre S, Pelletier G, Vaudry H (1987) Melanotropin release inhibiting activity of neuropeptide Y: structure-activity relationships. Life Sci 40(19):1875\u20131880. https:\/\/doi.org\/10.1016\/0024-3205(87)90045-2","journal-title":"Life Sci"},{"key":"5908_CR22","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/bip.22072","volume":"98","author":"JW Day","year":"2012","unstructured":"Day JW, Gelfanov V, Smiley D et al (2012) Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers 98:443\u2013450","journal-title":"Biopolymers"},{"issue":"2","key":"5908_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12433","volume":"11","author":"NA Di Prospero","year":"2021","unstructured":"Di Prospero NA, Yee J, Frustaci ME, Samtani MN, Alba M, Fleck P (2021) Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: a randomized dose-ranging study. Clin Obes 11(2):e12433. https:\/\/doi.org\/10.1111\/cob.12433","journal-title":"Clin Obes"},{"issue":"1","key":"5908_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm.3761","volume":"21","author":"B Finan","year":"2015","unstructured":"Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K, Campbell JE, Sandoval D, Seeley RJ, Bleicher K, Uhles S, Riboulet W, Funk J, Hertel C, Belli S, Sebokova E, Conde-Knape K, Konkar A, Drucker DJ, Gelfanov V, Pfluger PT, M\u00fcller TD, Perez-Tilve D, DiMarchi RD, Tsch\u00f6p MH (2015) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21(1):27\u201336. https:\/\/doi.org\/10.1038\/nm.3761","journal-title":"Nat Med"},{"key":"5908_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102129","volume":"96","author":"B Finan","year":"2025","unstructured":"Finan B, Douros JD, Goldwater R, Hansen AMK, Hjerpsted JB, Hj\u00f8llund KR, Kankam MK, Knerr PJ, Konkar A, Mowery SA, M\u00fcller TD, Nielsen JR, Nyg\u00e5rd SB, Perez-Tilve D, Raun K, Yang B, Tsch\u00f6p MH, DiMarchi RD (2025) A once-daily GLP-1\/GIP\/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans. Mol Metab 96:102129. https:\/\/doi.org\/10.1016\/j.molmet.2025.102129","journal-title":"Mol Metab"},{"key":"5908_CR26","doi-asserted-by":"publisher","unstructured":"Fosgerau K, Jessen L, Lind Tolborg J, \u00d8sterlund T, Schaeffer Larsen K, Rolsted K, Brorson M, Jelsing J, Skovlund Ryge Neerup T, Skovlund Ryge Neerup T (2013) The novel GLP-1-gastrin dual agonist, ZP3022, increases \u03b2-cell mass and prevents diabetes in db\/db mice. Diabetes Obes Metab 15(1):62\u201371. https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01676.x","DOI":"10.1111\/j.1463-1326.2012.01676.x"},{"issue":"1","key":"5908_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-3565(24)36577-2","volume":"281","author":"AA Fossa","year":"1997","unstructured":"Fossa AA, DePasquale MJ, Morrone J, Zorn SH, Bryce D, Lowe JA, McLean S (1997) Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog. J Pharmacol Exp Ther 281(1):180\u20137","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"5908_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1476-5381.2010.00867","volume":"161","author":"SM Gardiner","year":"2010","unstructured":"Gardiner SM, March JE, Kemp PA, Bennett T, Baker DJ (2010) Possible involvement of GLP-1(9\u201336) in the regional haemodynamic effects of GLP-1(7\u201336) in conscious rats. Br J Pharmacol 161(1):92\u2013102. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00867","journal-title":"Br J Pharmacol"},{"issue":"10499","key":"5908_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0140-6736(25)01176-6","volume":"406","author":"A Gasiorek","year":"2025","unstructured":"Gasiorek A, Heydorn A, Gabery S, Hjerpsted JB, Kirkeby K, Kruse T, Petersen SB, Toubro S, Vegge A, Key C (2025) Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. Lancet 406(10499):135\u2013148. https:\/\/doi.org\/10.1016\/S0140-6736(25)01176-6","journal-title":"Lancet"},{"issue":"4","key":"5908_CR30","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1476-5381.1995.tb14983.x","volume":"115","author":"AJ Gaw","year":"1995","unstructured":"Gaw AJ, Hills DM, Spraggs CF (1995) Characterization of the receptors and mechanisms involved in the cardiovascular actions of sCCK-8 in the pithed rat. Br J Pharmacol 115(4):660\u20134. https:\/\/doi.org\/10.1111\/j.1476-5381.1995.tb14983.x","journal-title":"Br J Pharmacol"},{"issue":"6","key":"5908_CR31","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1463-1326.2008.01018.x","volume":"11","author":"R Gentilella","year":"2009","unstructured":"Gentilella R, Bianchi C, Rossi A, Rotella CM (2009) Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab 11(6):544\u201356. https:\/\/doi.org\/10.1111\/j.1463-1326.2008.01018.x","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"5908_CR32","doi-asserted-by":"publisher","first-page":"6837","DOI":"10.1074\/jbc.M114.622670","volume":"290","author":"JP Goetze","year":"2015","unstructured":"Goetze JP, Johnsen AH, Kistorp C, Gustafsson F, Johnbeck CB, Rehfeld JF (2015) Cardiomyocyte expression and cell-specific processing of procholecystokinin. J Biol Chem 290(11):6837\u201343. https:\/\/doi.org\/10.1074\/jbc.M114.622670","journal-title":"J Biol Chem"},{"key":"5908_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.peptides.2018.08.004","volume":"108","author":"JP Goetze","year":"2018","unstructured":"Goetze JP, Hunter I, Zois NE, Terzic D, Valeur N, Olsen LH, Smith J, Plomgaard P, Hansen LH, Rehfeld JF, Balling L, Gustafsson F (2018) Cardiac procholecystokinin expression during haemodynamic changes in the mammalian heart. Peptides 108:7\u201313. https:\/\/doi.org\/10.1016\/j.peptides.2018.08.004","journal-title":"Peptides"},{"issue":"7","key":"5908_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/biology11070971","volume":"11","author":"JP Goetze","year":"2022","unstructured":"Goetze JP, Bartels ED, Shalmi TW, Andraud-Dang L, Rehfeld JF (2022) Biochemistry of the endocrine heart. Biology (Basel) 11(7):971. https:\/\/doi.org\/10.3390\/biology11070971","journal-title":"Biology (Basel)"},{"issue":"1","key":"5908_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5905374","volume":"2022","author":"ZN Han","year":"2022","unstructured":"Han ZN, Lin XX, Wang YY, Ding R, Hong L, Cui X (2022) Cholecystokinin octapeptide promotes ANP secretion through activation of NOX4-PGC-1\u03b1-PPAR\u03b1\/PPAR\u03b3 signaling in isolated beating rat atria. Oxid Med Cell Longev 2022(1):5905374. https:\/\/doi.org\/10.1155\/2022\/5905374","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"5908_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","volume":"82","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Browne SK, Suschak JJ, Tomah S, Gutierrez JA, Yang J, Roberts MS, Harris MS (2025) Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study. J Hepatol 82(1):7\u201317. https:\/\/doi.org\/10.1016\/j.jhep.2024.07.006","journal-title":"J Hepatol"},{"key":"5908_CR37","doi-asserted-by":"publisher","unstructured":"Hegner P, Baier MJ, Krammer T, Seitz S, K\u00e4s AK, Zschiedrich T, Lukas D, Lutz V, Wolf M, Sinha F, Schopka S, Schmid C, Kozakov K, Provaznik Z, Maier LS, Mustroph J, Wagner S (2026) Semaglutide improves contractile function in human atrial myocardium of patients with heart failure and preserved ejection fraction Cardiovasc Res. cvag039.\u00a0https:\/\/doi.org\/10.1093\/cvr\/cvag039","DOI":"10.1093\/cvr\/cvag039"},{"issue":"12","key":"5908_CR38","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/dom.12735","volume":"18","author":"SJ Henderson","year":"2016","unstructured":"Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, Jansson-L\u00f6fmark R, Naylor J, Rossi A, Bednarek MA, Bhagroo N, Salari H, Will S, Oldham S, Hansen G, Feigh M, Klein T, Grimsby J, Maguire S, Jermutus L, Rondinone CM, Coghlan MP (2016) Robust anti-obesity and metabolic eff ects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab 18(12):1176\u20131190. https:\/\/doi.org\/10.1111\/dom.12735","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"5908_CR39","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1038\/s42255-024-01113-9","volume":"6","author":"JJ Holst","year":"2024","unstructured":"Holst JJ (2024) GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management. Nat Metab 6(10):1866\u20131885. https:\/\/doi.org\/10.1038\/s42255-024-01113-9","journal-title":"Nat Metab"},{"key":"5908_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101024","volume":"39","author":"MK Holt","year":"2020","unstructured":"Holt MK, Cook DR, Brierley DI, Richards JE, Reimann F, Gourine AV, Marina N, Trapp S (2020) PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice. Mol Metab 39:101024. https:\/\/doi.org\/10.1016\/j.molmet.2020.101024","journal-title":"Mol Metab"},{"issue":"2","key":"5908_CR41","first-page":"77","volume":"19","author":"B Huisamen","year":"2008","unstructured":"Huisamen B, Genade S, Lochner A (2008) Signalling pathways activated by glucagon-like peptide-1 (7\u201336) amide in the rat heart and their role in protection against ischaemia. Cardiovasc J Afr 19(2):77\u201383","journal-title":"Cardiovasc J Afr"},{"key":"5908_CR42","doi-asserted-by":"publisher","unstructured":"Jastreboff AM, Ryan DH, Bays HE, Ebeling PR, Mackowski MG, Philipose N, Ross L, Liu Y, Burns CE, Abbasi SA, Pannacciulli N (2025) MariTide phase 2 obesity trial investigators. Once-monthly maridebart cafraglutide for the treatment of obesity-a phase 2 trial. N Engl J Med 393(9):843\u2013857. https:\/\/doi.org\/10.1056\/NEJMoa2504214","DOI":"10.1056\/NEJMoa2504214"},{"issue":"3","key":"5908_CR43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/14728214.2021.1947240","volume":"26","author":"MM Jepsen","year":"2021","unstructured":"Jepsen MM, Christensen MB (2021) Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs 26(3):231\u2013243. https:\/\/doi.org\/10.1080\/14728214.2021.1947240","journal-title":"Expert Opin Emerg Drugs"},{"key":"5908_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119815","volume":"282","author":"C Jons","year":"2021","unstructured":"Jons C, Porta-S\u00e1nchez A, Lai PFH, Wauchop M, Mass\u00e9 S, Azam MA, Asta J, Rose RA, Nanthakumar K (2021) Mechanism of and strategy to mitigate liraglutide-mediated positive chronotropy. Life Sci 282:119815. https:\/\/doi.org\/10.1016\/j.lfs.2021.119815","journal-title":"Life Sci"},{"issue":"2","key":"5908_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0196-9781(03)00041-x","volume":"24","author":"AC J\u00f6nsson-Rylander","year":"2003","unstructured":"J\u00f6nsson-Rylander AC, Nordlander M, Svindland A, Ilebekk A (2003) Distribution of neuropeptide Y Y1 and Y2 receptors in the postmortem human heart. Peptides 24(2):255\u2013262. https:\/\/doi.org\/10.1016\/s0196-9781(03)00041-x","journal-title":"Peptides"},{"key":"5908_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.npep.2015.08.006","volume":"54","author":"K Kaczy\u0144ska","year":"2015","unstructured":"Kaczy\u0144ska K, Szereda-Przestaszewska M (2015) Contribution of CCK1 receptors to cardiovascular and respiratory effects of cholecystokinin in anesthetized rats. Neuropeptides 54:29\u201334. https:\/\/doi.org\/10.1016\/j.npep.2015.08.006","journal-title":"Neuropeptides"},{"key":"5908_CR47","doi-asserted-by":"publisher","unstructured":"Killion EA, Chen M, Falsey JR, Sivits G, Hager T, Atangan L, Helmering J, Lee J, Li H, Wu B, Cheng Y, V\u00e9niant MM, Lloyd DJ (2020) Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. Nat Commun 11:4981 [RCA]. https:\/\/doi.org\/10.1038\/s41467-020-18751-8","DOI":"10.1038\/s41467-020-18751-8"},{"issue":"472","key":"5908_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat3392","volume":"10","author":"EA Killion","year":"2018","unstructured":"Killion EA, Wang J, Yie J, Shi SD, Bates D, Min X, Komorowski R, Hager T, Deng L, Atangan L, Lu SC, Kurzeja RJM, Sivits G, Lin J, Chen Q, Wang Z, Thibault SA, Abbott CM, Meng T, Clavette B, Murawsky CM, Foltz IN, Rottman JB, Hale C, V\u00e9niant MM, Lloyd DJ (2018) Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci Transl Med 10(472):eaat3392. https:\/\/doi.org\/10.1126\/scitranslmed.aat3392","journal-title":"Sci Transl Med"},{"issue":"5","key":"5908_CR49","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nm.3128","volume":"19","author":"M Kim","year":"2013","unstructured":"Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ (2013) GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 19(5):567\u2013575. https:\/\/doi.org\/10.1038\/nm.3128","journal-title":"Nat Med"},{"key":"5908_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J (2019) The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 10:155. https:\/\/doi.org\/10.3389\/fendo.2019.00155","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"5908_CR51","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.123.001045","volume":"77","author":"M Kokkorakis","year":"2025","unstructured":"Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, Ghezzawi M, Valenzuela-Vallejo L, Mantzoros CS (2025) Emerging pharmacotherapies for obesity: a systematic review. Pharmacol Rev 77(1):100002. https:\/\/doi.org\/10.1124\/pharmrev.123.001045","journal-title":"Pharmacol Rev"},{"issue":"7","key":"5908_CR52","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/ejhf.3644","volume":"27","author":"T Krammer","year":"2025","unstructured":"Krammer T, Baier MJ, Hegner P, Zschiedrich T, Lukas D, Wolf M, Le Phu C, Lutz V, Evert K, Kozakov K, Li J, Holzamer A, Maier LS, Provaznik Z, Bers DM, Wagner S, Mustroph J (2025) Cardioprotective eff ects of semaglutide on isolated human ventricular myocardium. Eur J Heart Fail 27(7):1315\u20131325. https:\/\/doi.org\/10.1002\/ejhf.3644","journal-title":"Eur J Heart Fail"},{"key":"5908_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105862","volume":"118","author":"RE Kuhre","year":"2025","unstructured":"Kuhre RE, Ballar\u00edn-Gonz\u00e1lez B, Brand CL, Glendorf T, Madsen KG, Hj\u00f8llund KR, Hogendorf WFJ, Ipsen DH, Lundh S, Kruse T, Petersen SB, Secher A, Vegge A, Raun K (2025) The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. EBioMedicine 118:105862. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105862","journal-title":"EBioMedicine"},{"issue":"15","key":"5908_CR54","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","volume":"187","author":"CM Kusminski","year":"2024","unstructured":"Kusminski CM, Perez-Tilve D, M\u00fcller TD, DiMarchi RD, Tsch\u00f6p MH, Scherer PE (2024) Transforming obesity: the advancement of multi-receptor drugs. Cell 187(15):3829\u20133853. https:\/\/doi.org\/10.1016\/j.cell.2024.06.003","journal-title":"Cell"},{"issue":"12","key":"5908_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1270-y","volume":"19","author":"HE Lebovitz","year":"2019","unstructured":"Lebovitz HE (2019) Thiazolidinediones: the forgotten diabetes medications. Curr Diab Rep 19(12):151. https:\/\/doi.org\/10.1007\/s11892-019-1270-y","journal-title":"Curr Diab Rep"},{"key":"5908_CR56","doi-asserted-by":"publisher","unstructured":"Lehnert F, Neumann J, Hofmann B, Gergs U (2026) Survodutide, a dual incretin-based agonist, exhibits a positive inotropic effect in isolated human atria. Clin Res Cardiol (2026) (P376). https:\/\/doi.org\/10.1007\/s00392-026-02870-1","DOI":"10.1007\/s00392-026-02870-1"},{"key":"5908_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2020.170459","volume":"136","author":"RS Leigh","year":"2021","unstructured":"Leigh RS, Ruskoaho HJ, Kaynak BL (2021) Cholecystokinin peptide signaling is regulated by a TBX5-MEF2 axis in the heart. Peptides 136:170459. https:\/\/doi.org\/10.1016\/j.peptides.2020.170459","journal-title":"Peptides"},{"issue":"33","key":"5908_CR58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2303696120","volume":"120","author":"Y Li","year":"2023","unstructured":"Li Y, Zhou Q, Dai A, Zhao F, Chang R, Ying T, Wu B, Yang D, Wang MW, Cong Z (2023) Structural analysis of the dual agonism at GLP-1R and GCGR. Proc Natl Acad Sci U S A 120(33):e2303696120. https:\/\/doi.org\/10.1073\/pnas.2303696120","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5908_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110311","volume":"120","author":"Q Liu","year":"2023","unstructured":"Liu Q, Zhu J, Kong B, Shuai W, Huang H (2023) Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4\/NF-kB\/NLRP3 pathway. Int Immunopharmacol 120:110311. https:\/\/doi.org\/10.1016\/j.intimp.2023.110311","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"5908_CR60","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/nu13030883","volume":"13","author":"VB Lu","year":"2021","unstructured":"Lu VB, Gribble FM, Reimann F (2021) Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion. Nutrients 13(3):883. https:\/\/doi.org\/10.3390\/nu13030883","journal-title":"Nutrients"},{"issue":"12","key":"5908_CR61","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/cvr\/cvae120","volume":"120","author":"AF Lubberding","year":"2024","unstructured":"Lubberding AF, Veedfald S, Achter JS, Nissen SD, Soattin L, Sorrentino A, Vega ET, Linz B, Eggertsen CHE, Mulvey J, Tor\u00e4ng S, Larsen SA, Nissen A, Petersen LG, Bilir SE, Bentzen BH, Rosenkilde MM, Hartmann B, Lille\u00f8r TNB, Qazi S, M\u00f8ller CH, Tfelt-Hansen J, Sattler SM, Jespersen T, Holst JJ, Lundby A (2024) Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node. Cardiovasc Res 120(12):1427\u20131441. https:\/\/doi.org\/10.1093\/cvr\/cvae120","journal-title":"Cardiovasc Res"},{"issue":"9","key":"5908_CR62","doi-asserted-by":"publisher","first-page":"11920","DOI":"10.1007\/s12035-025-05037-7","volume":"62","author":"H Ma","year":"2025","unstructured":"Ma H, Chang Z, Sun H, Ma D, Li Z, Hao L, Zhang Z, H\u00f6lscher C, Zhang Z (2025) A novel dual GLP-1\/CCK receptor agonist improves cognitive performance and synaptogenesis in the 5 \u00d7 FAD Alzheimer mouse model. Mol Neurobiol 62(9):11920\u201311934. https:\/\/doi.org\/10.1007\/s12035-025-05037-7","journal-title":"Mol Neurobiol"},{"key":"5908_CR63","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0167-0115(88)90081-x","volume":"20","author":"JD Marker","year":"1988","unstructured":"Marker JD, Roberts ML (1988) Chronotropic actions of cholecystokinin octapeptide on the rat heart. Regul Pept 20:251\u2013259. https:\/\/doi.org\/10.1016\/0167-0115(88)90081-x","journal-title":"Regul Pept"},{"issue":"2\u20133","key":"5908_CR64","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/s0014-2999(97)01258-2","volume":"336","author":"BJ McDermott","year":"1997","unstructured":"McDermott BJ, Millar BC, Dolan FM, Bell D, Balasubramaniam A (1997) Evidence for Y1 and Y2 subtypes of neuropeptide Y receptors linked to opposing postjunctional effects observed in rat cardiac myocytes. Eur J Pharmacol 336(2\u20133):257\u2013265. https:\/\/doi.org\/10.1016\/s0014-2999(97)01258-2","journal-title":"Eur J Pharmacol"},{"key":"5908_CR65","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","volume":"49","author":"E Melson","year":"2025","unstructured":"Melson E, Ashraf U, Papamargaritis D, Davies MJ (2025) What is the pipeline for future medications for obesity? Int J Obes (Lond) 49:433\u2013451. https:\/\/doi.org\/10.1038\/s41366-024-01473-y","journal-title":"Int J Obes (Lond)"},{"issue":"6","key":"5908_CR66","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1097\/00005344-198912000-00019","volume":"14","author":"MC Michel","year":"1989","unstructured":"Michel MC, Wirth SC, Zerkowski HR, Maisel AS, Motulsky HJ (1989) Lack of inotropic effects of neuropeptide Y in human myocardium. J Cardiovasc Pharmacol 14(6):919\u201322. https:\/\/doi.org\/10.1097\/00005344-198912000-00019","journal-title":"J Cardiovasc Pharmacol"},{"key":"5908_CR67","doi-asserted-by":"publisher","unstructured":"Mitko H, Neumann J, Hofmann B, Gergs U (2026) The dual incretin-based agonist mazdutide increased the contractile force in the human atrium. Clin Res Cardiol (2026) (P1381). https:\/\/doi.org\/10.1007\/s00392-026-02870-1","DOI":"10.1007\/s00392-026-02870-1"},{"issue":"6","key":"5908_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001295","volume":"19","author":"JI Mobbs","year":"2021","unstructured":"Mobbs JI, Belousoff MJ, Harikumar KG, Piper SJ, Xu X, Furness SGB, Venugopal H, Christopoulos A, Danev R, Wootten D, Thal DM, Miller LJ, Sexton PM (2021) Structures of the human cholecystokinin 1 (CCK1) receptor bound to Gs and Gq mimetic proteins provide insight into mechanisms of G protein selectivity. PLoS Biol 19(6):e3001295. https:\/\/doi.org\/10.1371\/journal.pbio.3001295","journal-title":"PLoS Biol"},{"issue":"5","key":"5908_CR69","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1124\/mol.108.054155","volume":"75","author":"T Moore-Morris","year":"2009","unstructured":"Moore-Morris T, Varrault A, Mangoni ME, Le Digarcher A, Negre V, Dantec C, Journot L, Nargeot J, Couette B (2009) Identification of potential pharmacological targets by analysis of the comprehensive G protein-coupled receptor repertoire in the four cardiac chambers. Mol Pharmacol 75(5):1108\u20131116. https:\/\/doi.org\/10.1124\/mol.108.054155","journal-title":"Mol Pharmacol"},{"issue":"5","key":"5908_CR70","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/CIRCEP.110.961037","volume":"4","author":"K Nair","year":"2011","unstructured":"Nair K, Umapathy K, Farid T, Masse S, Mueller E, Sivanandan RV, Poku K, Rao V, Nair V, Butany J, Ideker RE, Nanthakumar K (2011) Intramural activation during early human ventricular fibrillation. Circ Arrhythm Electrophysiol 4(5):692\u2013703. https:\/\/doi.org\/10.1161\/CIRCEP.110.961037","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"12","key":"5908_CR71","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1210\/en.2005-0237","volume":"146","author":"NM Neary","year":"2005","unstructured":"Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, Filipsson K, Wang F, Kent AS, Frost GS, Ghatei MA, Bloom SR (2005) Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 146(12):5120\u20137. https:\/\/doi.org\/10.1210\/en.2005-0237","journal-title":"Endocrinology"},{"issue":"5","key":"5908_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/pep2.24221","volume":"113","author":"JJ Nestor","year":"2021","unstructured":"Nestor JJ, Zhang X, Jaw-Tsai S, Parkes DG, Becker CK (2021) Design and characterization of a surfactant-conjugated, long-acting, balanced GLP-1\/glucagon receptor dual agonist. Pept Sci 113(5):e24221. https:\/\/doi.org\/10.1002\/pep2.24221","journal-title":"Pept Sci"},{"issue":"9","key":"5908_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16091139","volume":"16","author":"J Neumann","year":"2024","unstructured":"Neumann J, Hadova K, Klimas J, Hofmann B, Gergs U (2024) Contractile effects of semaglutide in the human atrium. Pharmaceutics (Basel) 16(9):1139. https:\/\/doi.org\/10.3390\/pharmaceutics16091139","journal-title":"Pharmaceutics (Basel)"},{"key":"5908_CR74","doi-asserted-by":"publisher","unstructured":"Neumann J, Ahlrep U, Hofmann B, Gergs U (2025a) Inotropic effects of retatrutide in isolated human atrial preparations. Naunyn-Schmiedeberg\u00b4s Arch Pharmacol 399(1):317\u2013327. https:\/\/doi.org\/10.1007\/s00210-025-04421-3","DOI":"10.1007\/s00210-025-04421-3"},{"key":"5908_CR75","doi-asserted-by":"publisher","unstructured":"Neumann J, Hofmann B, Kirchhefer U, Gergs U (2025b) Tirzepatide increased force of contraction in the isolated human arium. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 398(10):14451\u201314459. https:\/\/doi.org\/10.1007\/s00210-025-04214-8","DOI":"10.1007\/s00210-025-04214-8"},{"key":"5908_CR76","doi-asserted-by":"publisher","unstructured":"Neumann J, Hofmann B, Gergs U (2025c) Positive inotropic effects of glucose-dependent insulinotropic polypeptide in the human atrium and the mouse atrium. Naunyn-Schmiedeberg\u00b4s Arch Pharmacol 99(1):1067\u20131077. https:\/\/doi.org\/10.1007\/s00210-025-04485-1","DOI":"10.1007\/s00210-025-04485-1"},{"key":"5908_CR77","doi-asserted-by":"publisher","unstructured":"Neumann J, Hofmann B, Gergs U (2025d) Ubrogepant, erenumab and eptinezumab antagonize positive inotropic effects of the calcitonin gene-related peptide (CGRP) in the isolated human atrium. Naunyn-Schmiedeberg\u00b4s Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-04029-7","DOI":"10.1007\/s00210-025-04029-7"},{"key":"5908_CR78","doi-asserted-by":"publisher","unstructured":"Neumann J, Jarikova M, Kirchhefer U, Hofmann B, Gergs U (2026a) Contractile effects of albiglutide in the human and the mouse atrium. Front Endocrinol 17.\u00a0 https:\/\/doi.org\/10.3389\/fendo.2026.1831742","DOI":"10.3389\/fendo.2026.1831742"},{"key":"5908_CR79","doi-asserted-by":"publisher","unstructured":"Neumann J, Jarikova M, Hofmann B, Kirchhefer U, Gergs U (2026b) Contractile effects of dulaglutide in the human atrium. Naunyn-Schmiedeberg\u00b4s Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-026-05647-5","DOI":"10.1007\/s00210-026-05647-5"},{"issue":"4","key":"5908_CR80","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3390\/pharmaceutics18040447","volume":"18","author":"J Neumann","year":"2026","unstructured":"Neumann J, Kirchefer U, Hofmann B (2026c) Gergs U (2026c) Acute contractile effects of glucagon-like-peptide-1 receptor agonists in the human heart. Pharmaceutics 18(4):447. https:\/\/doi.org\/10.3390\/pharmaceutics18040447","journal-title":"Pharmaceutics"},{"issue":"10520","key":"5908_CR81","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1016\/S0140-6736(25)02114-2","volume":"406","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Harrison SA, Loomba R, Alkhouri N, Chalasani N, Sheikh MY, Tomah S, Gutierrez JA, Urbina S, Suschak JJ, Brown R, Odili O, Yang J, Keeton S, Neff G, Mena E, Roberts MS, Browne SK, Harris MS (2025) Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week resultsfrom a multicentre, randomised, double-blind, phase 2b study. Lancet 406(10520):2644\u20132655. https:\/\/doi.org\/10.1016\/S0140-6736(25)02114-2","journal-title":"Lancet"},{"key":"5908_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2023.171003","volume":"165","author":"A Novikoff","year":"2023","unstructured":"Novikoff A, M\u00fcller TD (2023) The molecular pharmacology of glucagon agonists in diabetes and obesity. Peptides 165:171003. https:\/\/doi.org\/10.1016\/j.peptides.2023.171003","journal-title":"Peptides"},{"issue":"15","key":"5908_CR83","doi-asserted-by":"publisher","first-page":"8268","DOI":"10.1002\/anie.202016464","volume":"60","author":"S Oestergaard","year":"2021","unstructured":"Oestergaard S, Paulsson JF, Kjaergaard Gerstenberg M, Wulff BS (2021) The design of a GLP-1\/PYY dual acting agonist. Angew Chem Int Ed Engl 60(15):8268\u20138275. https:\/\/doi.org\/10.1002\/anie.202016464","journal-title":"Angew Chem Int Ed Engl"},{"issue":"2","key":"5908_CR84","doi-asserted-by":"publisher","first-page":"94","DOI":"10.14744\/AnatolJCardiol.2024.4719","volume":"29","author":"Y Olgar","year":"2025","unstructured":"Olgar Y, Durak A, Turan B (2025) Acute GLP-1 agonism induces arrhythmogenic electrical activity in aged mice heart through impaired cellular Na+ and Ca2+ handlings: The role of CK2 hyperphosphorylation. Anatol J Cardiol 29(2):94. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2024.4719","journal-title":"Anatol J Cardiol"},{"issue":"1","key":"5908_CR85","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/17460441.2025.2601113","volume":"21","author":"S \u00d8stergaard","year":"2026","unstructured":"\u00d8stergaard S (2026) Advancing obesity treatments through innovations in the design and manufacturing of therapeutic peptides. Expert Opin Drug Discov 21(1):49\u201372. https:\/\/doi.org\/10.1080\/17460441.2025.2601113","journal-title":"Expert Opin Drug Discov"},{"issue":"8","key":"5908_CR86","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s42255-022-00617-6","volume":"4","author":"C Quarta","year":"2022","unstructured":"Quarta C, Stemmer K, Novikoff A, Yang B, Klingelhuber F, Harger A, Bakhti M, Bastidas-Ponce A, Baug\u00e9 E, Campbell JE, Capozzi M, Clemmensen C, Collden G, Cota P, Douros J, Drucker DJ, DuBois B, Feuchtinger A, Garcia-Caceres C, Grandl G, Hennuyer N, Herzig S, Hofmann SM, Knerr PJ, Kulaj K, Lalloyer F, Lickert H, Liskiewicz A, Liskiewicz D, Maity G, Perez-Tilve D, Prakash S, Sanchez-Garrido MA, Zhang Q, Staels B, Krahmer N, DiMarchi RD, Tsch\u00f6p MH, Finan B, M\u00fcller TD (2022) GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice. Nat Metab 4(8):1071\u20131083. https:\/\/doi.org\/10.1038\/s42255-022-00617-6","journal-title":"Nat Metab"},{"issue":"5","key":"5908_CR87","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.celrep.2016.03.091","volume":"15","author":"RD Ramracheya","year":"2016","unstructured":"Ramracheya RD, McCulloch LJ, Clark A, Wiggins D, Johannessen H, Olsen MK, Cai X, Zhao CM, Chen D, Rorsman P (2016) PYY-dependent restoration of impaired insulin and glucagon secretion in type 2 diabetes following Roux-en-Y gastric bypass surgery. Cell Rep 15(5):944\u2013950. https:\/\/doi.org\/10.1016\/j.celrep.2016.03.091","journal-title":"Cell Rep"},{"key":"5908_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-0115(96)00135-8","volume":"61","author":"JP Raufman","year":"1996","unstructured":"Raufman JP (1996) Bioactive peptides from lizard venoms. Regul Pept 61:1\u201318","journal-title":"Regul Pept"},{"key":"5908_CR89","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1016\/S0021-9258(18)49932-2","volume":"266","author":"JP Raufman","year":"1991","unstructured":"Raufman JP, Singh L, Eng J (1991) Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas. Description of exendin-3(9-39)amide, a specific exendin receptor antagonist. J Biol Chem 266:2897\u20132902","journal-title":"J Biol Chem"},{"issue":"6","key":"5908_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102156","volume":"6","author":"R Rodriguez","year":"2025","unstructured":"Rodriguez R, Hergarden A, Krishnan S, Morales M, Lam D, Tracy T, Tang T, Patton A, Lee C, Pant A, Erlanson DA, Enquist J, Bone D, Fucini R, Bialonczyk D, Hansen SK, Luo J, Chakravarthy MV (2025) Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R\/GIPR biased agonism yielding greater efficacy. Cell Rep Med 6(6):102156. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102156","journal-title":"Cell Rep Med"},{"key":"5908_CR91","doi-asserted-by":"publisher","unstructured":"Rodriguez R, Tracy T, Morales M, Hergarden A, Lam D, Krishnan S, Morales M, Hansen SK, Chakravarthy MV (2023) Biased GLP-1 improves weight loss with additional benefits on glucose homeostasis via biased GIP in diabetic rodent models.\u00a0Diabetes 72(Supplement_1):1649\u2013P.\u00a0https:\/\/doi.org\/10.2337\/db23-1649-P","DOI":"10.2337\/db23-1649-P"},{"key":"5908_CR92","doi-asserted-by":"publisher","unstructured":"Romero-G\u00f3mez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, Kaufman KD, Engel SS, MK-6024 P001 Study Group (2023) A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol 79(4):888\u2013897. https:\/\/doi.org\/10.1016\/j.jhep.2023.05.013","DOI":"10.1016\/j.jhep.2023.05.013"},{"key":"5908_CR93","doi-asserted-by":"publisher","unstructured":"Rudzki G, Knop-Chody\u0142a K, Piasecka Z, Kochanowska-Mazurek A, G\u0142az A, Weso\u0142ek-Bielaska E, Wo\u017aniak M (2024) Managing post-transplant diabetes mellitus after kidney transplantation: challenges and advances in treatment. Pharmaceuticals (Basel) 17:987 [RCA]. https:\/\/doi.org\/10.3390\/ph17080987","DOI":"10.3390\/ph17080987"},{"issue":"5","key":"5908_CR94","doi-asserted-by":"publisher","first-page":"E600","DOI":"10.1152\/ajpendo.00371.2023","volume":"327","author":"P Sangwung","year":"2024","unstructured":"Sangwung P, Ho JD, Siddall T, Lin J, Tomas A, Jones B, Sloop KW (2024) Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease. Am J Physiol Endocrinol Metab 327(5):E600\u2013E615. https:\/\/doi.org\/10.1152\/ajpendo.00371.2023","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"11","key":"5908_CR95","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1007\/s00125-025-06525-0","volume":"68","author":"PCF Schreier","year":"2025","unstructured":"Schreier PCF, Beyerle P, Boulassel S, Beck A, Novikoff A, Reinach PS, Boekhoff I, Breit A, Neuberger A, M\u00fcller TD, Serrano AC, Gudermann T, Khajavi N (2025) GLP-1\/GIP\/GCG receptor triagonist (IUB447) enhances insulin secretion via GLP-1 receptor and G\u03b1q signalling pathway in mice. Diabetologia 68(11):2567\u20132580. https:\/\/doi.org\/10.1007\/s00125-025-06525-0","journal-title":"Diabetologia"},{"key":"5908_CR96","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cbpa.2014.07.024","volume":"178","author":"H Seth","year":"2014","unstructured":"Seth H, Axelsson M, Gr\u00e4ns A (2014) The peptide hormone cholecystokinin modulates the tonus and compliance of the bulbus arteriosus and pre-branchial vessels of the rainbow trout (Oncorhynchus mykiss). Comp Biochem Physiol A Mol Integr Physiol 178:18\u201323. https:\/\/doi.org\/10.1016\/j.cbpa.2014.07.024","journal-title":"Comp Biochem Physiol A Mol Integr Physiol"},{"key":"5908_CR97","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaf036","author":"JW Son","year":"2025","unstructured":"Son JW, le Roux CW, Bl\u00fcher M, Nauck MA, Lim S (2025) Novel GLP-1-based medications for type 2 diabetes and obesity. Endocr Rev. https:\/\/doi.org\/10.1210\/endrev\/bnaf036","journal-title":"Endocr Rev"},{"issue":"2","key":"5908_CR98","doi-asserted-by":"publisher","first-page":"R962","DOI":"10.1152\/ajpregu.00405.2006","volume":"292","author":"GL Sowden","year":"2007","unstructured":"Sowden GL, Drucker DJ, Weinshenker D, Swoap SJ (2007) Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. Am J Physiol Regul Integr Comp Physiol 292(2):R962\u2013R970. https:\/\/doi.org\/10.1152\/ajpregu.00405.2006","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"5908_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01281","volume":"9","author":"CMJ Tan","year":"2018","unstructured":"Tan CMJ, Green P, Tapoulal N, Lewandowski AJ, Leeson P, Herring N (2018) The role of neuropeptide Y in cardiovascular health and disease. Front Physiol 9:1281. https:\/\/doi.org\/10.3389\/fphys.2018.01281","journal-title":"Front Physiol"},{"key":"5908_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.674704","volume":"12","author":"N Tanday","year":"2021","unstructured":"Tanday N, English A, Lafferty RA, Flatt PR, Irwin N (2021) Benefits of sustained upregulated unimolecular GLP-1 and CCK receptor signalling in obesity-diabetes. Front Endocrinol (Lausanne) 12:674704. https:\/\/doi.org\/10.3389\/fendo.2021.674704","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"5908_CR101","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/dom.13494","volume":"21","author":"J Tillner","year":"2019","unstructured":"Tillner J, Posch MG, Wagner F, Teichert L, Hijazi Y, Einig C, Keil S, Haack T, Wagner M, Bossart M, Larsen PJ (2019) A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diabetes Obes Metab 21(1):120\u2013128. https:\/\/doi.org\/10.1111\/dom.13494","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"5908_CR102","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1203\/00006450-199902000-00018","volume":"45","author":"CE Tseng","year":"1999","unstructured":"Tseng CE, Miranda E, Di Donato F, Boutjdir M, Rashbaum W, Chan EK, Buyon JP (1999) mRNA and protein expression of SSA\/Ro and SSB\/La in human fetal cardiac myocytes cultured using a novel application of the Langendorff procedure. Pediatr Res 45(2):260\u2013269. https:\/\/doi.org\/10.1203\/00006450-199902000-00018","journal-title":"Pediatr Res"},{"issue":"5","key":"5908_CR103","doi-asserted-by":"publisher","first-page":"507e","DOI":"10.1016\/j.molmet.2014.04.009","volume":"3","author":"JR Ussher","year":"2014","unstructured":"Ussher JR, Baggio LL, Campbell JE, Mulvihill EE, Kim M, Kabir MG et al (2014) Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol Metab 3(5):507e\u20135517","journal-title":"Mol Metab"},{"key":"5908_CR104","doi-asserted-by":"publisher","unstructured":"V\u00e9niant MM, Lu SC, Atangan L, Komorowski R, Stanislaus S, Cheng Y, Wu B, Falsey JR, Hager T, Thomas VA, Ambhaikar M, Sharpsten L, Zhu Y, Kurra V, Jeswani R, Oberoi RK, Parnes JR, Honarpour N, Neutel J, Strande JL (2024) A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab 6:290\u2013303 [RCA]. https:\/\/doi.org\/10.1038\/s42255-023-00966-w","DOI":"10.1038\/s42255-023-00966-w"},{"issue":"Pt B","key":"5908_CR105","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.yjmcc.2015.09.018","volume":"89","author":"M Wallner","year":"2015","unstructured":"Wallner M, Kolesnik E, Ablasser K, Khafaga M, Wakula P, Ljubojevic S, Thon-Gutschi EM, Sourij H, Kapl M, Edmunds NJ, Kuzmiski JB, Griffith DA, Knez I, Pieske B, von Lewinski D (2015) Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. J Mol Cell Cardiol 89(Pt B):365\u2013375. https:\/\/doi.org\/10.1016\/j.yjmcc.2015.09.018","journal-title":"J Mol Cell Cardiol"},{"issue":"11","key":"5908_CR106","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1479-5876-11-84","volume":"28","author":"P Wohlfart","year":"2013","unstructured":"Wohlfart P, Linz W, H\u00fcbschle T, Linz D, Huber J, Hess S, Crowther D, Werner U, Ruetten H (2013) Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies. J Transl Med 28(11):84. https:\/\/doi.org\/10.1186\/1479-5876-11-84","journal-title":"J Transl Med"},{"key":"5908_CR107","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6820377","author":"D Xu","year":"2022","unstructured":"Xu D, Nair A, Sigston C, Ho C, Li J, Yang D, Liao X, Chen W, Kuang M, Li Y, Reid C, Xiao H (2022) Potential roles of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in nondiabetic populations. Cardiovasc Ther. https:\/\/doi.org\/10.1155\/2022\/6820377","journal-title":"Cardiovasc Ther"},{"key":"5908_CR108","unstructured":"Yagiz K, Barker G, Barnes M, Stevens E et al (n.d.) Novel co-agonists of GLP-1 and GIP receptors produce robust weight loss in a rodent model of obesity. Poster (#206) presented at the annual meeting of The Obesity Society (ObesityWeek\u00ae 2021) (link)"},{"key":"5908_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114001","volume":"177","author":"E Yuliantie","year":"2020","unstructured":"Yuliantie E, Darbalaei S, Dai A, Zhao P, Yang D, Sexton PM, Wang MW, Wootten D (2020) Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors. Biochem Pharmacol 177:114001. https:\/\/doi.org\/10.1016\/j.bcp.2020.114001","journal-title":"Biochem Pharmacol"},{"issue":"17","key":"5908_CR110","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1111\/bph.15860","volume":"179","author":"S Zhao","year":"2022","unstructured":"Zhao S, Yan Z, Du Y, Li Z, Tang C, Jing L, Sun L, Yang Q, Tang X, Yuan Y, Han J, Jiang N (2022) A GLP-1\/glucagon (GCG)\/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes. Br J Pharmacol 179(17):4360\u20134377. https:\/\/doi.org\/10.1111\/bph.15860","journal-title":"Br J Pharmacol"},{"issue":"22","key":"5908_CR111","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.3748\/wjg.v11.i22.3405","volume":"11","author":"XY Zhao","year":"2005","unstructured":"Zhao XY, Ling YL, Li YG, Meng AH, Xing HY (2005) Cholecystokinin octapeptide improves cardiac function by activating cholecystokinin octapeptide receptor in endotoxic shock rats. World J Gastroenterol 11(22):3405\u20133410. https:\/\/doi.org\/10.3748\/wjg.v11.i22.3405","journal-title":"World J Gastroenterol"},{"issue":"1","key":"5908_CR112","first-page":"31","volume":"56","author":"XY Zhao","year":"2004","unstructured":"Zhao XY, Ling YL, Shang ZL, Li Q, Yin JX, Tan GJ (2004) Cholecystokinin octapeptide increases free intracellular calcium of guinea pig cardiomyocytes through activation of Ca2+ channel and tyrosine kinase. Sheng Li Xue Bao 56(1):31\u201335","journal-title":"Sheng Li Xue Bao"},{"key":"5908_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2022.170811","volume":"153","author":"F Zhou","year":"2022","unstructured":"Zhou F, Song P, Tang X, Yang Q, Zhou S, Xu R, Fang T, Jia Z, Han J (2022J) Discovery of once-weekly, peptide-based selective GLP-1 and cholecystokinin 2 receptors co-agonists. Peptides 153:170811. https:\/\/doi.org\/10.1016\/j.peptides.2022.170811","journal-title":"Peptides"},{"issue":"9","key":"5908_CR114","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202200130","volume":"7","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Huang S, Li C, Qiao Y, Liu Q, Chen T, Wang J, Liu Y (2023) Glucagon-Like Peptide-1 (GLP-1) Rescue diabetic cardiac dysfuntions in human iPSC-derived cardiomyocytes. Adv Biol (Weinh) 7(9):e2200130. https:\/\/doi.org\/10.1002\/adbi.202200130","journal-title":"Adv Biol (Weinh)"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05908-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05908-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05908-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:39:35Z","timestamp":1790041175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05908-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":114,"alternative-id":["5908"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05908-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Does not apply.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Does not apply.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have seen and approved the submitted version of this manuscript.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}